Novartis and Eli Lilly are exiting the neurological disease therapy developer in an acquisition that will involve $52.5m upfront and up to $250m in milestone payments.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The spinout has revealed it added approximately $6m to a series A round backed by University of Pennsylvania and IP Group last year, bringing its total size to about $59m.

The M12-backed healthcare data management platform is speaking to new investors and is targeting between $50m and $60m at a $300m valuation.

The company has revealed it added approximately $6m to a series A round co-led by AbbVie Ventures last year, bringing its total size to about $59m.

Taiho, Memorial Sloan Kettering Cancer Center and Hartford HealthCare contributed to a round that boosted the cancer drug developer's total funding to more than $175m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Oxford Brain Diagnostics hopes to commercialise an early diagnosis tool for Alzheimer’s disease pioneered through eight years of University of Oxford research.

Bayer will pay up to $600 for the 59.2% stake in engineered-cell therapy developer BlueRock Therapeutics it does now own, following a $225m round in 2016.